Cargando…

Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

OBJECTIVES: Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, ‘high-risk’ and ‘low-risk’) with tofacitinib versus tumour necrosis factor inhibitors (TNFi). METHODS: Patients with rheuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristensen, Lars Erik, Danese, Silvio, Yndestad, Arne, Wang, Cunshan, Nagy, Edward, Modesto, Irene, Rivas, Jose, Benda, Birgitta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314011/
https://www.ncbi.nlm.nih.gov/pubmed/36931693
http://dx.doi.org/10.1136/ard-2022-223715
_version_ 1785067229994287104
author Kristensen, Lars Erik
Danese, Silvio
Yndestad, Arne
Wang, Cunshan
Nagy, Edward
Modesto, Irene
Rivas, Jose
Benda, Birgitta
author_facet Kristensen, Lars Erik
Danese, Silvio
Yndestad, Arne
Wang, Cunshan
Nagy, Edward
Modesto, Irene
Rivas, Jose
Benda, Birgitta
author_sort Kristensen, Lars Erik
collection PubMed
description OBJECTIVES: Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, ‘high-risk’ and ‘low-risk’) with tofacitinib versus tumour necrosis factor inhibitors (TNFi). METHODS: Patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times a day or TNFi. Prior analyses had identified age and smoking as risk factors of particular interest across safety outcomes. Hazard ratios (HRs) and incidence rates were evaluated by age and smoking individually and in combination. Results were validated across tofacitinib development programmes. RESULTS: ‘Age ≥65 years or ever smoker’ defined a group (‘high-risk’) with increased risk of malignancies (excluding non-melanoma skin cancer), major adverse cardiovascular events, myocardial infarction, venous thromboembolism and all-cause death with tofacitinib (combined doses) versus TNFi (HRs 1.41–5.19). In patients ‘aged <65 years and never smokers’ (’low-risk’), there was no detectable risk increase with tofacitinib versus TNFi (HRs ≈1.0) up to 6 years of follow-up, and absolute risk remained low and was corroborated across tofacitinib rheumatoid arthritis, psoriatic arthritis and ulcerative colitis programmes with up to 10 years of observation. CONCLUSIONS: This posthoc analysis of ORAL Surveillance identified two tofacitinib subpopulations with different relative risk versus TNFi. High risk was confined to patients defined by distinct risk factors age ≥65 years or smoking, and these differentiating risk factors accounted for the excess risk observed with tofacitinib versus TNFi. These findings can guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib. TRIAL REGISTRATION NUMBERS: NCT02092467, NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02281552, NCT02187055, NCT02831855, NCT00413699, NCT00661661, NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612, NCT01877668, NCT01882439, NCT01976364.
format Online
Article
Text
id pubmed-10314011
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-103140112023-07-02 Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance Kristensen, Lars Erik Danese, Silvio Yndestad, Arne Wang, Cunshan Nagy, Edward Modesto, Irene Rivas, Jose Benda, Birgitta Ann Rheum Dis Rheumatoid Arthritis OBJECTIVES: Based on primary results from ORAL Surveillance, an event-driven clinical trial of risk-enriched patients, identify subpopulations with different relative risk (ie, ‘high-risk’ and ‘low-risk’) with tofacitinib versus tumour necrosis factor inhibitors (TNFi). METHODS: Patients with rheumatoid arthritis aged ≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times a day or TNFi. Prior analyses had identified age and smoking as risk factors of particular interest across safety outcomes. Hazard ratios (HRs) and incidence rates were evaluated by age and smoking individually and in combination. Results were validated across tofacitinib development programmes. RESULTS: ‘Age ≥65 years or ever smoker’ defined a group (‘high-risk’) with increased risk of malignancies (excluding non-melanoma skin cancer), major adverse cardiovascular events, myocardial infarction, venous thromboembolism and all-cause death with tofacitinib (combined doses) versus TNFi (HRs 1.41–5.19). In patients ‘aged <65 years and never smokers’ (’low-risk’), there was no detectable risk increase with tofacitinib versus TNFi (HRs ≈1.0) up to 6 years of follow-up, and absolute risk remained low and was corroborated across tofacitinib rheumatoid arthritis, psoriatic arthritis and ulcerative colitis programmes with up to 10 years of observation. CONCLUSIONS: This posthoc analysis of ORAL Surveillance identified two tofacitinib subpopulations with different relative risk versus TNFi. High risk was confined to patients defined by distinct risk factors age ≥65 years or smoking, and these differentiating risk factors accounted for the excess risk observed with tofacitinib versus TNFi. These findings can guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib. TRIAL REGISTRATION NUMBERS: NCT02092467, NCT01262118, NCT01484561, NCT00147498, NCT00413660, NCT00550446, NCT00603512, NCT00687193, NCT01164579, NCT00976599, NCT01059864, NCT01359150, NCT02147587, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385, NCT01039688, NCT02281552, NCT02187055, NCT02831855, NCT00413699, NCT00661661, NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612, NCT01877668, NCT01882439, NCT01976364. BMJ Publishing Group 2023-07 2023-03-17 /pmc/articles/PMC10314011/ /pubmed/36931693 http://dx.doi.org/10.1136/ard-2022-223715 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Rheumatoid Arthritis
Kristensen, Lars Erik
Danese, Silvio
Yndestad, Arne
Wang, Cunshan
Nagy, Edward
Modesto, Irene
Rivas, Jose
Benda, Birgitta
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
title Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
title_full Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
title_fullStr Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
title_full_unstemmed Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
title_short Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
title_sort identification of two tofacitinib subpopulations with different relative risk versus tnf inhibitors: an analysis of the open label, randomised controlled study oral surveillance
topic Rheumatoid Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314011/
https://www.ncbi.nlm.nih.gov/pubmed/36931693
http://dx.doi.org/10.1136/ard-2022-223715
work_keys_str_mv AT kristensenlarserik identificationoftwotofacitinibsubpopulationswithdifferentrelativeriskversustnfinhibitorsananalysisoftheopenlabelrandomisedcontrolledstudyoralsurveillance
AT danesesilvio identificationoftwotofacitinibsubpopulationswithdifferentrelativeriskversustnfinhibitorsananalysisoftheopenlabelrandomisedcontrolledstudyoralsurveillance
AT yndestadarne identificationoftwotofacitinibsubpopulationswithdifferentrelativeriskversustnfinhibitorsananalysisoftheopenlabelrandomisedcontrolledstudyoralsurveillance
AT wangcunshan identificationoftwotofacitinibsubpopulationswithdifferentrelativeriskversustnfinhibitorsananalysisoftheopenlabelrandomisedcontrolledstudyoralsurveillance
AT nagyedward identificationoftwotofacitinibsubpopulationswithdifferentrelativeriskversustnfinhibitorsananalysisoftheopenlabelrandomisedcontrolledstudyoralsurveillance
AT modestoirene identificationoftwotofacitinibsubpopulationswithdifferentrelativeriskversustnfinhibitorsananalysisoftheopenlabelrandomisedcontrolledstudyoralsurveillance
AT rivasjose identificationoftwotofacitinibsubpopulationswithdifferentrelativeriskversustnfinhibitorsananalysisoftheopenlabelrandomisedcontrolledstudyoralsurveillance
AT bendabirgitta identificationoftwotofacitinibsubpopulationswithdifferentrelativeriskversustnfinhibitorsananalysisoftheopenlabelrandomisedcontrolledstudyoralsurveillance